. 2006 Oct 25;81(2):599–612. doi: 10.1128/JVI.01739-06

TABLE 1.

Patient characteristics for 32 study subjects

Study subject	Count (cells/mm³)		Log₁₀ plasma viral load (copies/ml)	Stage^a	Estimated duration of infection^b (days)
Study subject	CD4	CD8	Log₁₀ plasma viral load (copies/ml)	Stage^a	Estimated duration of infection^b (days)
102	391	312	7.11	Ia	18
100	595	1,259	5.47	II	45
104	1,321	926	5.79	II	38
107	426	928	5.61	Ia	24
336	556	1,368	4.99	II	62
109	340	803	6.26	II	19
119	350	1,354	6.33	Ia	18
122	400	1,086	4.95	III	72
125	684	855	5.03	II	36
127	350	1,075	4.99	Ia	23
131	250	959	6.75	Ia	25
137	178	1,325	5.94	Ia	31
500	311	1,464	5.23	Ia	27
347	291	679	4.43	Ia	64
128	706	2,638	4.57	Ia	29
141	489	1,146	4.94	III	88
142	330	575	4.22	II	NA
143	442	621	5.17	Ia	28
351	956	1,017	3.42	II	NA
357	514	1,218	3.75	III	NA
146	391	633	4.52	I	51
147	194	267	5.97	Ia	30
502	408	3,011	7.46	Ia	19
503	631	607	5.66	Ia	18
508	176	2,116	5.74	Ia	26
148	332	754	5.40	II	87
512	820	1,598	6.51	Ia	38
368	346	1,070	4.62	II	NA
516	372	906	4.49	II	59
519	322	976	6.26	Ia	27
518	434	527	6.72	Ia	19
520	473	917	4.91	Ia	30
Mean	462	1,093	5.41		37

Subjects were staged in accordance with the NIH-sponsored AIEDRP as follows: ELISA negative (stage Ia), Western blot indeterminate (stage Ib), nonreactive detuned ELISA result with an OD of <0.5 or a documented negative ELISA result within 3 months of presentation (stage II), and a nonreactive detuned ELISA result (OD of 0.51 to 1.0) or a documented negative serology within 6 months of presentation (stage III).

The estimated duration of infection was calculated 2 weeks prior to the onset of acute retroviral illness. In four subjects, the estimated duration of infection could not be calculated. Enrollment was based on nonreactive detuned ELISA result (stage II) or a documented negative HIV-1 test within the 6 months of biopsy (stage III). NA, not available.